Co promotion agreement for dapagliflozinCo-Promotion Agreement • April 7th, 2023
Contract Type FiledApril 7th, 2023AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.
Co promotion agreement for dapagliflozinCo-Promotion Agreement • May 3rd, 2021
Contract Type FiledMay 3rd, 2021AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.